Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

por Smolej, Lukáš, Vodárek, Pavel, Écsiová, Dominika, Šimkovič, Martin
Publicado 2021

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia

por Vodárek, Pavel, Écsiová, Dominika, Řezáčová, Vladimíra, Souček, Ondřej, Šimkovič, Martin, Vokurková, Doris, Belada, David, Žák, Pavel, Smolej, Lukáš
Publicado 2022

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

por Šimkovič, Martin, Motyčková, Monika, Belada, David, Vodárek, Pavel, Kapoor, Rahul, Jaffar, Hamna, Vrbacký, Filip, Žák, Pavel, Smolej, Lukáš
Publicado 2015

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

por Šimkovič, Martin, Turcsányi, Peter, Špaček, Martin, Mihályová, Jana, Ryznerová, Pavlína, Maco, Mária, Vodárek, Pavel, Écsiová, Dominika, Poul, Hynek, Móciková, Heidi, Zuchnická, Jana, Panovská, Anna, Lekaa, Mohammad, Oršulová, Martina, Prchlíková, Adéla, Stejskal, Lukáš, Mašlejová, Stanislava, Brychtová, Yvona, Bezděková, Lucie, Papajík, Tomáš, Lysák, Daniel, Trněný, Marek, Smolej, Lukáš, Doubek, Michael
Publicado 2023